Augmentation of VAMP-catalytic activity of botulinum neurotoxin serotype B does not result in increased potency in physiological systems

Botulinum neurotoxins (BoNTs) are used extensively as therapeutic agents. Serotypes A and B are available as marketed products. Higher doses of BoNT/B are required to reach an efficacy similar to that of products containing BoNT/A. Advances in our understanding of BoNT/B mechanism of action have aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Elliott, Mark, Maignel, Jacquie, Liu, Sai Man, Favre-Guilmard, Christine, Mir, Imran, Farrow, Paul, Hornby, Fraser, Marlin, Sandra, Palan, Shilpa, Beard, Matthew, Krupp, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628846/
https://www.ncbi.nlm.nih.gov/pubmed/28982136
http://dx.doi.org/10.1371/journal.pone.0185628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628846/
https://www.ncbi.nlm.nih.gov/pubmed/28982136
http://dx.doi.org/10.1371/journal.pone.0185628

Ejemplares similares